This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to comprehensively study glial activation and iron dysregulation in brain tissue samples from patients with Frontotemporal Lobar Degeneration (FTLD). The $803,111 award, which runs from December 2024 to November 2029, will enable researchers at the University of Pennsylvania to model and contrast the microscopic, mesoscopic, and macroscopic progression of neuroinflammation, abnormal iron...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research into proteostasis, neuroinflammation, and neurodegeneration in frontotemporal dementia (FTD). The $630,496 award, granted on June 1, 2025, aims to better define alterations in proteostasis in FTD glial cells, including microglia and astrocytes, and determine if proteostasis impairment in glia, neurons, or both drives neurodegeneration in FTD. The research is being conducted by the J....
The National Institute on Aging (NIA) awarded a $2,126,420 Project Grant (CFDA 93.866 - Aging Research) to The Trustees of the University of Pennsylvania to evaluate retinal imaging biomarkers that can distinguish frontotemporal lobar degeneration (FTLD) subtypes and differentiate FTLD from non-amnestic Alzheimer's disease. The 3-year project aims to use optical coherence tomography to identify retinal abnormalities that may serve as non-invasive biomarkers for the underlying tau, TDP-43, or...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $786,632 to Northwestern University to conduct a comprehensive scientific investigation into the anatomic, pathologic, and molecular signatures of frontotemporal lobar degeneration with transactive response DNA-binding protein type C (FTLD-TDP type C). The award, effective December 1, 2024 through November 30, 2029, will enable the university's Primary Progressive Aphasia (PPA)...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $104,164 to Emory University to conduct research on the role of the TMEM106B gene in neurodegenerative disorders, particularly frontotemporal dementia (FTD). The research aims to: 1) Determine the interaction between TMEM106B and the C9ORF72 gene, which is linked to FTD and amyotrophic lateral sclerosis, and 2) Investigate the toxicity of TMEM106B protein aggregates and their impact on...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $404,058 to the Regents of the University of Minnesota to develop a novel approach to restore functional TDP43 for the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The goal is to identify small molecule compounds that can stabilize functional, multimeric forms of the TDP43 protein to prevent its loss of function and toxic aggregation, which are...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $791,086 to the Northern California Institute for Research and Education, Inc. (NCIRE) to develop computational models that can predict the presence of non-Alzheimer's disease neuropathological changes, such as Lewy body disease, TDP-43 proteinopathy, and cerebral amyloid angiopathy, in individuals with Alzheimer's disease neuropathological changes. The goal is to create clinically translatable...
The National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), awarded a $1,076,760 Project Grant to the Vlaams Instituut Voor Biotechnologie (VIB) in Belgium. The grant, which runs from Sep 30, 2024 to Aug 31, 2029, supports research to develop a humanized frontotemporal lobar degeneration (FTLD-TDP) mouse model and identify molecular factors secreted by microglia that contribute to FTLD-related neurodegeneration. Additionally, the project aims to determine the...
This Project Grant award of $4,787,820, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports a research project titled "PREDICT ADRD: PREDICTING THE EFFECTS OF DIAGNOSIS IN INDIVIDUALS ACROSS COUNTRIES AND TIME IN ADRD". The primary goals are to: 1) examine the relationship between cognitive decline and workforce exit for older adults in the U.S., England, and 28 European countries; 2) assess the concordance between survey-based cognitive tests and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop multi-analyte algorithms for screening and prognosis of frontotemporal lobar degeneration (FTLD), a family of neurodegenerative proteinopathies. The $2,398,069 award to The Trustees of the University of Pennsylvania will leverage a unique cohort of over 200 pathology-confirmed FTLD cases to pathologically validate biomarkers of neurodegeneration, neuroinflammation, and synaptic dysfunction. The study will map disease cascades in FTLD subtypes and develop diagnostic and prognostic algorithms, which will be verified in an independent replication sample. Findings are expected to advance the understanding of FTLD biology and expand the FTLD biomarker toolkit. The award period is from September 30, 2024 to June 30, 2029.